US medical devices industry saw a drop of 7.84% in overall deal activity during January 2022, when compared with the last 12-month average, led by Owens & Minor’s $1.6bn acquisition of Apria, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 94 deals worth $4.7bn were announced in January 2022, compared with the 12-month average of 102 deals.
venture financing was the leading category in the month in terms of volume with 54 deals, which accounted for 57.5% of all deals.
In second place was M&A with 31 deals, followed by private equity with nine transactions, respectively accounting for 33% and 9.6% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $3.26bn, while venture financing and private equity deals totalled $1.17bn and $250m respectively.
US medical devices industry deals in January 2022: Top deals
The top five medical devices industry deals accounted for 67.7% of the overall value during January 2022.
The combined value of the top five medical devices deals stood at $3.16bn, against the overall value of $4.7bn recorded for the month.
The top five medical devices industry deals of January 2022 tracked by GlobalData were:
1) Owens & Minor $1.6bn acquisition deal with Apria
2) The $623m acquisition of GeneDX by Sema4 OpCo
3) ConvaTec Group $450m acquisition deal with Triad Life Sciences
4) The $250m private equity of Fluidigm by Casdin Capital and Viking Global Investors
5) Maravai LifeSciences Holdings $240m acquisition deal with MyChem
